Company news
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) news
Catalyst Pharmaceuticals, Inc. news releases on 6ix. Latest, Jun 30, 2026: Vamorolone Demonstrates On-Target Glucocorticoid Activity Without…
Press releases & updates
Vamorolone Demonstrates On-Target Glucocorticoid Activity Without the Immunosuppression Characteristic of Traditional Corticosteroids at Clinical Doses
June 30, 2026
Catalyst Pharmaceuticals Reports First Quarter 2026 Financial Results
May 11, 2026
Angelini Pharma to Acquire Catalyst Pharmaceuticals for 4.1 Billion USD (3.5 Billion Euros), Entering the U.S. Market and Consolidating its Leadership in Brain Health and Rare Disease
May 7, 2026
Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Hetero Labs Ltd.
May 7, 2026
Catalyst Pharmaceuticals to Report First Quarter 2026 Financial Results on May 11, 2026
April 28, 2026
Catalyst Pharmaceuticals to Showcase Real‑World Findings in Duchenne Muscular Dystrophy and Host Vamorolone-Focused Symposium at the 2026 MDA Clinical & Scientific Conference
March 5, 2026
Catalyst Pharmaceuticals Reports Record Fourth Quarter and Record Full Year 2025 Financial Results and Provides 2026 Financial Guidance
February 25, 2026
Catalyst Pharmaceuticals to Participate in the Barclays 28th Annual Global Healthcare Conference
February 24, 2026
Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026
February 11, 2026
Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2026 List of America's Most Successful Small-Cap Companies
January 8, 2026
The University of Notre Dame and Catalyst Pharmaceuticals Host Inaugural Catalyst Advocacy Scholars Summit (CASS)
January 4, 2026
Catalyst Pharmaceuticals to Participate in the 44th Annual J.P. Morgan Healthcare Conference
December 14, 2025
Catalyst Pharmaceuticals to Participate in the Bank of America CNS Therapeutics Virtual Conference
November 23, 2025
Catalyst Pharmaceuticals Recognized as One of North America’s Fastest-Growing Companies on the 2025 Deloitte Technology Fast 500™
November 18, 2025
Catalyst Pharmaceuticals to Participate in Citi’s 2025 Global Healthcare Conference
November 17, 2025
Catalyst Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
November 4, 2025
Catalyst Pharmaceuticals Recognized Among BioSpace 2026 Best Places to Work
November 3, 2025
Catalyst Pharmaceuticals to Participate in Jefferies Global Healthcare Conference
November 2, 2025
Catalyst Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 5, 2025
October 21, 2025
Catalyst Pharmaceuticals Announces Presentations at Upcoming Scientific Conferences
October 8, 2025
Santhera Announces Approval in Canada for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy
October 3, 2025
Catalyst Pharmaceuticals Announces $200 Million Share Repurchase Program
September 30, 2025
Santhera Secures CHF 20 Million Growth Funding to Accelerate Global AGAMREE® Rollout
September 23, 2025
Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences
August 27, 2025
UPDATED- Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Lupin Pharmaceuticals
August 26, 2025
Lambert Eaton Myasthenic Syndrome (LEMS) Antibody Testing and Treatment Recommendations Added to NCCN Clinical Practice Guidelines for Small Cell Lung Cancer (SCLC)
August 5, 2025
Catalyst Pharmaceuticals Reports Record Second Quarter and First Half 2025 Financial Results; Provides Business Update
August 5, 2025
Catalyst Pharmaceuticals Appoints Daniel Curran, MD, to its Board of Directors
August 3, 2025
Catalyst Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 6, 2025
July 21, 2025
Catalyst Pharmaceuticals Announces Appointment of William T. Andrews, MD, FACP as Chief Medical Officer
June 1, 2025
Catalyst Pharmaceuticals Reports Record First Quarter 2025 Financial Results and Provides Business Update
May 6, 2025
Catalyst Pharmaceuticals to Participate in the BofA Securities Health Care Conference 2025
April 29, 2025
Catalyst Pharmaceuticals to Report First Quarter 2025 Financial Results on May 7, 2025
April 21, 2025
New Drug Submission for AGAMREE® (vamorolone) Accepted for Priority Review by Health Canada for the Treatment of Duchenne Muscular Dystrophy
April 7, 2025
Catalyst Pharmaceuticals Announces Health Canada’s Acceptance of AGAMREE® New Drug Submission with Priority Review for Sub-Licensee Kye Pharmaceuticals
April 7, 2025
Catalyst Pharmaceuticals to Participate in the Barclays 27th Annual Global Healthcare Conference
March 3, 2025
Catalyst Pharmaceuticals Reports Record Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
February 25, 2025
Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2024 Financial Results on February 26, 2025
February 11, 2025
Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2025 List of America's Most Successful Mid-Cap Companies
January 22, 2025
Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Launched FIRDAPSE® in Japan
January 20, 2025
Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Teva Pharmaceuticals
January 7, 2025
Catalyst Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
December 15, 2024
Catalyst Pharmaceuticals Recognized as One of North America’s Fastest-Growing Companies on the 2024 Deloitte Technology Fast 500™ List
November 24, 2024
Catalyst Pharmaceuticals Recognized Among BioSpace 2025 Best Places to Work
November 12, 2024
Catalyst Pharmaceuticals Reports Strong Third Quarter 2024 Financial Results and Provides Corporate Update
November 5, 2024
Catalyst Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 6, 2024
October 21, 2024
Catalyst Pharmaceuticals Donates $100,000 to the American Red Cross Hurricane Helene Relief Efforts
October 7, 2024
Catalyst Pharmaceuticals to Participate in the BofA Securities CNS Therapeutics Virtual Conference 2024
September 30, 2024
Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Received Approval to Commercialize FIRDAPSE® in Japan
September 23, 2024
Catalyst Pharmaceuticals Reports Strong Second Quarter 2024 Financial Results and Provides Corporate Update
August 6, 2024